Hormone therapy and gallbladder disease: what route evidence shows
Oral estrogen regimens raised gallbladder events in randomized WHI data. A large observational study found a smaller association with transdermal treatment, but that route comparison was not randomized.
Systemic menopausal hormone therapy has a gallbladder warning. Randomized Women’s Health Initiative data found more gallbladder disease and surgery with the studied oral estrogen regimens than with placebo. An observational study associated transdermal therapy with a smaller increase than oral therapy, but it does not prove that a patch removes risk or is the right route for any one person.123
This is a particular organ and outcome question, not a general verdict on hormone therapy. Gallstones, symptomatic gallbladder disease, and gallbladder surgery are not interchangeable endpoints. A person with prior cholecystectomy also has a different history to describe than someone with an imaging report of silent stones.
What the randomized oral-regimen evidence measures
The WHI analysis compared oral conjugated equine estrogens (CEE), alone or with oral medroxyprogesterone acetate (MPA), against placebo in its respective study populations. It reported increased gallbladder-disease or surgery outcomes: hazard ratios approximately 1.67 for CEE alone and 1.59 for CEE plus MPA. A hazard ratio is a group-level comparison over follow-up, not the probability that a particular person will need surgery. These results should be attributed to the studied oral regimens rather than every estradiol patch or progesterone formulation.2
The current estradiol transdermal label still includes a gallbladder disease warning. That is a reason to discuss a personal history even when a patch is proposed; it is not proof that the WHI oral estimate is the patch’s risk. Labels may include class-related evidence and warnings beyond a product-specific route trial.1
What the route study adds—and cannot settle
In the Million Women Study’s observational analysis, the reported relative risk versus never-users was about 1.74 for oral users and 1.17 for transdermal users. The route contrast is clinically relevant research, but participants were not randomly assigned to patch or pill. Differences in who selected or was prescribed each route may influence the association. It cannot produce a personal “patch is safe” conclusion from the numbers alone.3
| Evidence | Strongest supported reading | Overreach |
|---|---|---|
| WHI randomized oral regimens | Oral CEE regimens increased the studied gallbladder outcomes | The same hazard ratio applies to every modern patch |
| Observational patch-versus-pill study | A smaller association appeared in transdermal users | Route alone caused the difference in every patient |
| Current patch label | Gallbladder history remains relevant | The label gives an individual risk calculator |
Bring any prior gallstone diagnosis, gallbladder surgery, current symptom workup, and the exact therapy being considered to the consultation. Ask which outcome the clinician is discussing and how the evidence for that product and route applies to your history. Our patch-versus-pill guide covers broader route considerations; this page keeps the gallbladder endpoint in focus. Compare hormone-therapy providers to find a service that can review the records rather than relying on a generic route slogan.
Why the endpoint matters in a medical history
“Gallbladder problem” can refer to stones seen on imaging, a documented inflammatory episode, a hospitalization, or an operation. The WHI paper’s composite of gallbladder disease and surgery is not a count of every abdominal symptom in the trial. A person describing nausea after starting a medicine cannot use that paper to identify its cause; conversely, an old silent imaging finding should not be equated automatically with the trial’s outcome. The clinician needs the actual diagnosis and records to interpret relevance.2
The route study reports gallbladder disease associated with oral and transdermal therapy in a large observational population. It is tempting to subtract the two relative risks and call the difference the patch’s personal protection. That arithmetic would be unsound: different baseline risks, treatment selection, and adherence may all matter, and an observational association is not a randomized switch experiment. The appropriate reading is that route may be relevant and deserves discussion, while the comparative causal effect remains uncertain.3
Keep a second medication question separate
Many people arriving at a menopause consultation also have a weight-management history. Some GLP-1 labels and studies raise their own gallbladder questions. The GLP-1 gallbladder guide addresses that product family. It would be a mistake to attribute an event to estrogen because the patient uses HRT, or to a GLP-1 medicine because it is newer, without examining dates, diagnoses, and the complete product record. Two concurrent exposures do not create one pooled risk number.
The useful clinician question is: which exact gallbladder outcome do you think is relevant to me, and which study or label covers the regimen you are proposing? A good answer can acknowledge both the randomized oral evidence and the observational transdermal uncertainty. That is more informative than either “all HRT causes gallstones” or “patches cannot affect the gallbladder.”
Sources
- National Library of Medicine DailyMed. Estradiol transdermal system prescribing information. Section 5.4 retains an estrogen-related gallbladder disease warning; this is a patch label, not a patch-specific randomized risk estimate. Accessed .
- PubMed. Estrogen therapy and gallbladder disease in the Women's Health Initiative. Randomized oral CEE and oral CEE-plus-MPA evidence for gallbladder disease and surgery. Accessed .
- PubMed. Gallbladder disease and use of transdermal versus oral hormone replacement therapy. Observational route comparison; possible confounding prevents a randomized causal route claim. Accessed .